Search hospitals > North Carolina > Durham

Duke Comprehensive Cancer Center

Claim this profile
Durham, North Carolina 27705
Global Leader in Brain Tumor
Global Leader in Solid Tumors
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
625 reported clinical trials
36 medical researchers
Photo of Duke Comprehensive Cancer Center in DurhamPhoto of Duke Comprehensive Cancer Center in DurhamPhoto of Duke Comprehensive Cancer Center in Durham

Summary

Duke Comprehensive Cancer Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Brain Tumor, Solid Tumors, Breast Cancer, Lung Cancer, Cancer and other specialties. Duke Comprehensive Cancer Center is involved with conducting 625 clinical trials across 395 conditions. There are 36 research doctors associated with this hospital, such as Angeles A. Secord, Harry P. Erba, Jeffrey M. Clarke, and Richard Riedel, MD.

Area of expertise

1Brain Tumor
Global Leader
Duke Comprehensive Cancer Center has run 94 trials for Brain Tumor. Some of their research focus areas include:
Stage IV
HER2 positive
Stage III
2Solid Tumors
Global Leader
Duke Comprehensive Cancer Center has run 79 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive

Top PIs

Clinical Trials running at Duke Comprehensive Cancer Center

Breast Cancer
Ovarian Cancer
Cancer
Colorectal Cancer
Solid Tumors
Lung Cancer
Fallopian Tube Cancer
Pancreatic Cancer
Brain Tumor
Non-Hodgkin's Lymphoma
Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab

for Triple Negative Breast Cancer

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Image of trial facility.

Zanidatamab vs Trastuzumab

for Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

SRG-514

for Breast Cancer

This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Recruiting1 award Phase 13 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Duke Comprehensive Cancer Center?
Where is Duke Comprehensive Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Duke Comprehensive Cancer Center accept?
What awards or recognition has Duke Comprehensive Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security